VGT-309

The FDA granted Fast Track designation to abenacianine (VGT-309) for improved visualization of lung tumors during surgery, addressing a critical unmet need.

Vergent Bioscience has completed enrollment in its Phase 2 VISUALIZE trial evaluating abenacianine for injection (VGT-309) in lung cancer patients.

The FDA granted priority review to sunvozertinib for treating advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Vergent Bioscience completed enrollment in its Phase 2 VISUALIZE trial evaluating abenacianine for injection (VGT-309) to improve tumor visualization during lung cancer surgery.